PTC/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMM.
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMM.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control in

	Application Number			
	Filing Date		2006-06-26	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mura		urakami et al.	
Not for submission under 37 CFR 1.99)	Art Unit			
not for submission and or or it may	Examiner Name			
	Attorney Docket Numb	er	24179965-000005	

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Decument Relevan			s,Columns,Lines where ant Passages or Relevant es Appear		
	1										
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button. Add										
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of stad Document			es,Columns,Lines where want Passages or Relevant res Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Applicant of cited		vhere Rel	or Relevant	Ţ5
	1	11-296345	JP			1999-10-29	Hitachi Ltd.				
	2	2001-68993	JP			2001-03-16	Fuji Xerox Co., Ltd				
	3	2001-202236	JP			2001-07-27	Fuii Xerox Co. Ltd.				П

Application Number Fing Date 2006-06-26 Fing Date 2006-06-26 First Number (Not for submission under 37 CFR 1.99) Application Number 2006-06-26 First Number (Not for submission under 37 CFR 1.99) At Unit Carminer Name Attorney Cooket Number (2417995-000005)

	4	2003-198362	JP		2003-07-11	Tokyo Electron Device Ltd.		
	5	2003-029969	JP		2003-01-31	Tokyo Electron Device Ltd.		
If you wis	h to a	ı dd additional Foreign	Patent Document	citation	information pl	lease click the Add butto	Add	_
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catabg, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тs	
	1 PCT/JP2004019819, International Search Report and Written Opinion of International Searching Authority, April 5, 2005.							
If you wis	h to a	dd additional non-pal	ent literature docu	ment ci	tation informat	ion please click the Add	outton Add	
			EX	CAMINE	R SIGNATUR	E		
Examiner	Signa	ture				Date Considered		
*FVALUE	ED. I-	W-1 W-4					Daniella a Manuale a	

Take Kint Code of USPTO Petert Documents at Invest/ISPTO.000/c or MPEP 901.04. Tester of tice that issued the document, by the Involved roods (WIPO Standard ST.3). "For impresse patient comment, the involved on the year of the register or impressed the seath undervied the patient code (WIPO Standard ST.3). "For impressed the seath undervied the patient code (WIPO Standard ST.3). "For impression is standard standard ST.3 ("For impression standard ST.3 ("For impr

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Fing Date 2006-06-26 First Number (Not for submission under 37 CFR 1.99) Application Number 2006-06-26 First Number Number Number Number Number Number 2417995-000005

CERTIFICATION STATEMENT

Please see 37	000 4 00	 	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William D. McSpadden/	Date (YYYY-MM-DD)	2006-06-26
Name/Drint	William D. McSnadden	Registration Number	44234

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.